Clinical Trial Update: AutoLogous Human CArdiac-Derived Stem Cell to Treat Ischemic cArdiomyopathy (ALCADIA) [Phase 1]

View source ↗

Summary

Completion of a Phase 1 trial evaluating autologous cardiac-derived stem cells (ALCADIA) for ischemic cardiomyopathy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Ischemic Cardiomyopathy

Snippet

Sponsor: Naofumi Takehara | Conditions: Congestive Heart Failure, Ischemic Cardiomyopathy | Phase 1 | Status: COMPLETED